FDA gives ap­proval to No­var­tis' man­u­fac­tur­ing site for Plu­vic­to

No­var­tis said Fri­day that the pro­duc­tion fa­cil­i­ty for its ra­di­oli­gand ther­a­py Plu­vic­to has got­ten the thumbs-up from the FDA, and it plans to be­gin sup­ply­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA